CCR1 Monoclonal Antibody Blocking CCL15 Receptor Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anti-CCR1 antibodies have not been developed as pharmaceuticals and lack sufficient performance as antibody pharmaceuticals for treating CCR1-related diseases.
Innovation Solution
A human CCR1 monoclonal antibody that binds to the extracellular region of CCR1 and inhibits activation by human CCL15, with specific CDR sequences for varying antibody variants, including chimeric, humanized, and human antibodies, and their fragments, used in therapeutic and diagnostic agents for CCR1-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-CCR1 antibodies are used, then CCR1 binding is achieved, but insufficient performance as pharmaceuticals and lack of development as therapeutics occurs
Solution Approach 1:
The patent applies parameter changes by modifying the antibody structure to achieve human IgG1 or IgG4 constant regions with specific isoelectric points (pI ≥ 4.0), thereby improving pharmaceutical performance and enabling therapeutic development while maintaining CCR1 binding capability
2Reliability
If a monoclonal antibody is developed to bind human CCR1 and inhibit activation by human CCL15, then CCR1 activation inhibition is achieved, but complexity in antibody design and production increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody into distinct functional components: variable regions (VL and VH) with specific CDR sequences for CCR1 binding, and constant regions (CL and CH) with controlled pI values for pharmaceutical performance, thereby achieving activation inhibition while managing design complexity through modular structure definition
3Ease of manufacture
If existing antibodies are used without further development, then simplicity in current state is maintained, but insufficient information on performance as antibody pharmaceuticals remains
Solution Approach 1:
The patent applies preliminary action by pre-defining specific antibody structures with controlled pI values and constant region types (IgG1 or IgG4) before pharmaceutical testing, thereby generating performance information in advance and reducing the loss of pharmaceutical data while maintaining manufacturing simplicity through standardized designs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The monoclonal antibody effectively inhibits CCR1 activation and cell migration, providing therapeutic and diagnostic options for CCR1-related diseases such as cancer, autoimmune diseases, and inflammatory diseases.
Implementation Method 1
a monoclonal antibody or an antibody fragment thereof which binds to an extracellular region of a CCR1 and inhibits activation of the human CCR1 by a human CCL 15
Data Source
AI summary
A monoclonal antibody is provided which binds to a human CC chemokine receptor 1 (CCR1) and inhibits activation of the human CCR1, or an antibody fragment thereof. The monoclonal antibody binds to an extracellular region of a human CCR1 and inhibits activation of the human CCR1 by a human CC chemokine ligand 15 (CCL15). An antibody fragment thereof, a hybridoma producing the antibody, a nucleic acid having a nucleotide sequence encoding the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment using the hybridoma or the transformant cell; a therapeutic agent and a diagnostic agent containing the antibody or the antibody fragment, and a method for treating and diagnosing a CCR1-related disease using the antibody or the antibody fragment are also provided.